Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alphatec Holdings (ATEC – Research Report), Vertex ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Alltrna’s CEO Michelle Warner said that the approach allows for basket trials that can group patients with different diseases ...

AbbVie, Danaher, Organovo, Thermo Fisher Scientific, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of ...

Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...